These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14045304)

  • 21. Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.
    Adhikari D; Roy TB; Biswas A; Chakraborty ML; Bhattacharya B; Maitra TK; Basu AK; Chandra S
    Indian Pediatr; 1995 Aug; 32(8):855-61. PubMed ID: 8635827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of hemochromatosis mutations on iron overload of thalassemia major.
    Longo F; Zecchina G; Sbaiz L; Fischer R; Piga A; Camaschella C
    Haematologica; 1999 Sep; 84(9):799-803. PubMed ID: 10477452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
    Naderi M; Sadeghi-Bojd S; Valeshabad AK; Jahantigh A; Alizadeh S; Dorgalaleh A; Tabibian S; Bamedi T
    Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia.
    Arcasoy A; Cavdar AO
    Acta Haematol; 1975; 53(6):341-6. PubMed ID: 808939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [ON SOME PARTICULAR ASPECTS OF IRON KINETICS IN SUBJECTS WITH THALASSEMIA MAJOR].
    PRIOLISI A; GIUFFRE L
    Pediatria (Napoli); 1964 Jun; 72():467-92. PubMed ID: 14170507
    [No Abstract]   [Full Text] [Related]  

  • 26. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.
    Angelopoulos NG; Goula A; Rombopoulos G; Kaltzidou V; Katounda E; Kaltsas D; Tolis G
    J Bone Miner Metab; 2006; 24(2):138-45. PubMed ID: 16502121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [IRON EXCHANGE IN VARIOUS ANEMIC-HEMOLYTIC CONSTITUTIONAL BLOOD DISEASE: THALASSEMIA MAJOR, ELLIPTOCYTIC ANEMIA].
    SCHETTINI F
    Pediatria (Napoli); 1964; 72():29-38. PubMed ID: 14163249
    [No Abstract]   [Full Text] [Related]  

  • 28. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers.
    Melis MA; Cau M; Deidda F; Barella S; Cao A; Galanello R
    Haematologica; 2002 Mar; 87(3):242-5. PubMed ID: 11869934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [DESFERRIOXAMINE (DF) AND DIETHYLENE TRIAMINE PENTA-ACETIC ACID TRISODIUM CALCIUM SALT (CA DTPA NA3) IN SIDEROSIS. 2].
    ALBAHARY C
    Presse Med (1893); 1965 Jan; 73():73-6. PubMed ID: 14234334
    [No Abstract]   [Full Text] [Related]  

  • 30. IN VITRO HEME SYNTHESIS BY HUMAN BLOOD: ABNORMAL HEME SYNTHESIS IN THALASSEMIA MAJOR.
    VAVRA JD; MAYER VK; MOORE CV
    J Lab Clin Med; 1964 May; 63():736-53. PubMed ID: 14158058
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
    McLaren GD; Muir WA; Kellermeyer RW
    Crit Rev Clin Lab Sci; 1983; 19(3):205-66. PubMed ID: 6373141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging (MRI) findings of joints in young beta-thalassemia major patients: fluid surrounding the scaphoid bone: a novel finding, as the possible effect of secondary hemochromatosis.
    Karimi M; Jamalian N; Rasekhi A; Kashef S
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):393-8. PubMed ID: 17551401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CHELATING TREATMENT OF HEMOCHROMATOSIS WITH DESFERRIOXAMINE BY MOUTH AND PARENTERAL ADMINISTRATION].
    ANGELINO PF; FERRO GF; VACCA G; MEDICI L
    Minerva Med; 1964 Jan; 55():75-7. PubMed ID: 14128430
    [No Abstract]   [Full Text] [Related]  

  • 34. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray crystallographic analyses of complexes between bovine beta-trypsin and Schiff base copper(II) or iron(III) chelates.
    Toyota E; Ng KK; Sekizaki H; Itoh K; Tanizawa K; James MN
    J Mol Biol; 2001 Jan; 305(3):471-9. PubMed ID: 11152605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [TREATMENT OF HEMOCHROMATOSIS CAUSED BY COOLEY'S ANEMIA BY DESFERRIOXAMINE. PRELIMINARY RESULTS].
    NEIMANN N; PIERSON M; MANCIAUX M; VERT P; SCHAACK JC
    Med Infant (Paris); 1965 Feb; 72():105-11. PubMed ID: 14300339
    [No Abstract]   [Full Text] [Related]  

  • 37. THE NEW CHELATING AGENT CA-DTPA IN THE TREATMENT OF PRIMARY HAEMOCHROMATOSIS.
    KEMBLE JV
    Guys Hosp Rep; 1964; 113():68-73. PubMed ID: 14114732
    [No Abstract]   [Full Text] [Related]  

  • 38. SODIUM, POTASSIUM, CALCIUM, MAGNESIUM, COPPER, AND ZINC COMPOSITION OF ERYTHROCYTES IN VITAMIN B12 DEFICIENCY AND IRON DEFICIENCY.
    VALBERG LS; HOLT JM; BROWN GM
    J Clin Invest; 1965 Jul; 44(7):1225-33. PubMed ID: 14328398
    [No Abstract]   [Full Text] [Related]  

  • 39. THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
    WOEHLER F
    Acta Haematol; 1963 Aug; 30():65-87. PubMed ID: 14064792
    [No Abstract]   [Full Text] [Related]  

  • 40. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH; Grady RW; Cerami A
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.